Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
@Bob
The market runs its own affairs. The stock is obviously drawn to its recent turning point at 1.89. If they announced the exclusive licensing of their cancer applications, for an upfront of half a billion, the market would have no choice. But there is always some excuse. I suppose, if West introduced mice that can regrow eyes, ears and legs, and are expected to last 1,000 years, we’d drop to an all-time low. I wish I could load, but none of what I‘m trying to sell, is even trading today. And what I could sell, I don’t feel like selling.
Hi All, it's Bob from the Yahoo AGE message board setting up shop here in Investor's Hub. Peter, PAR75 and Felix - you all are welcome to DM me if you are set up over here. I've got an item I'd like to discuss with you.
Retards shorting premarket will end up getting burned up after the open.
Yummy! AGE $AGE
We shall see. Tomorrow could get interesting.
Great day of action! Held strong... next leg coming???
Agreed then back up we go! Low floater here with big money behind it!
Institutional investors make shorters
VERY NERVOUS.
Especially if they have a 50% stake.
They're covering now. IMO
There could be a huge squeeze here.
ExOr
Half the float locked up by institutional investors here. See where she goes.
AGE THIN ASK TO $6 AND 50% OF SHARES HELD BY INSTITUTION.
* * $AGE Video Chart 10-08-2020 * *
Link to Video - click here to watch the technical chart video
Thank you Crudeoil24.
Juvenescence Limited must be highly regarded in the industry.
AgeX Therapeutics shares are trading higher following an amended 13D filing showing Juvenescence Limited has a 50% stake in the company.
AGE
As far as this massive dol vol wants to take it until news flow hits glta
Someone in the great white north texted his buddies that they just struck a great vein!
Just joking!
But clearly someone knows something right glty!
Best of cont'd success to all here! Been some excellent monsters like this one dating all the way back to KODK which has been an awesome addition to the HOT OTC casino we've had for most of this year!
Does anybody have an idea why the huge volume and price spikes with AGE today?
to the moon
Keep on banking Pedro! We got trade em not marry em when they're awakenin' hotties right cheers>>>$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
I was in at $2.50 -- I got scared -- and I sold at $3.00
Looking for another entry
MA$$IVE big boy vol pouring in folks!!!
Insane in the membrane weeeeeeeeeeeeeeeeeee
AGE ASK THIN ALL THE WAY TO $5.
what in the heck happened?
* * $AGE Video Chart 05-29-2020 * *
Link to Video - click here to watch the technical chart video
Confusion regarding AgeX and LCTX collaboration/competition
LCTX states
"We have entered into three separate agreements with entities in the cell therapy space for the license, development, manufacture and sale of products based on our broad cell therapy platform and technologies."
Subsequently on 12/30 AgeX states...
" Going forward we plan to strengthen our capacity of executing on external licensing and collaboration deals with third parties as well as in-house cell therapy product development."
Does anyone have a clear idea or a website that explains who is selling what? When AgeX split from BTX/LCTX who owns the rights to which patents, etc.?
Any clarification would be greatly appreciated.
NOTE: I'm posting this on both the LCTX and the AgeX sites.
Agex & Juvenescence publish in a peer-reviewed journal "Regenerative Medicine"
LINK: https://www.agexinc.com/investors-media/single-news-story/?id=6626
Article:
Logo Logo Logo Logo Logo
About Us
Leadership
Technology
Pipeline
Investors
Contact Us
AgeX Therapeutics and Juvenescence Publish Paper on Engineering Strategies for Universal Cells and Provide in Vivo Observation on Immunotolerance UniverCyteTM Technology Platform
10/30/2019
Paper published in peer-reviewed journal Regenerative Medicine
UniverCyteTM platform aims to utilize proprietary, novel, modified form of immunomodulatory molecule HLA-G to generate universal allogeneic cells to enable off-the-shelf therapeutics without the need for immunosuppressants
Previously unpublished in vivo observation signals that UniverCyte-modified allogeneic cells may be potentially hypoimmunogenic in humanized mouse model
Co-authors are Drs. Nafees Malik and Gregory Bailey of AgeX and Juvenescence, Dr. Annalisa Jenkins of AgeX, and Jim Mellon, Chairman of Juvenescence
ALAMEDA, Calif. & DOUGLAS, Isle of Man--(BUSINESS WIRE)--Oct. 30, 2019-- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Juvenescence, a life sciences company developing therapeutics and technologies to treat diseases of aging and to increase human longevity, announce the publication of a new paper in the peer-reviewed scientific journal Regenerative Medicine. The paper is on the engineering of allogeneic cells to be hypoimmunogenic (universal), so as not to produce an immune response. The strategies reviewed in the paper include deletion of human leukocyte antigen (HLA) class Ia/II proteins, expression of HLA class Ib molecules, and manipulation of immune checkpoints.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191030005329/en/
In addition, the paper presents a previously unpublished in vivo observation on allogeneic human pluripotent stem cells (hPSCs) modified with AgeX’s proprietary immunotolerance technology, UniverCyteTM. In humanized mice (those with a functional human immune system), UniverCyte-positive hPSCs formed larger and heavier tissue compared to controls. This observation provides support for the premise that UniverCyte-expressing tissue was potentially hypoimmunogenic and might have escaped recognition by a functional human immune system and continued to grow. Further work is required to substantiate this preliminary in vivo finding.
“Hypoimmunogenic allogeneic cells are the Holy Grail in regenerative medicine, and a number of accomplished researchers have made great strides toward engineering them over the last few years,” commented Dr. Nafees Malik, Chief Operating Officer at AgeX, Head of Cell & Gene Therapy at Juvenescence (a major investor in AgeX), and lead author on the paper. “This is a huge area of focus for us at AgeX, via our UniverCyte technology platform. In support of our own research and as a service to the overall field, we decided to put together this paper, analyzing all the leading strategies to engineer universal cells and encapsulating them in one paper.”
Dr. Malik’s co-authors on the paper are Gregory Bailey, MD, Chairman of the Board of Directors of AgeX and CEO of Juvenescence; Annalisa Jenkins, MBBS, FRCP, who serves on the Board of Directors of AgeX; and Jim Mellon, Chairman of Juvenescence.
Mr. Mellon added, “AgeX’s UniverCyte technology platform will not only be important to the company in developing in-house therapies, it may also be transformative for the wider cell therapy industry via collaborations and licensing deals. It is quite conceivable that in the near future, allogeneic cell therapies may potentially need to be universal to be clinically and commercially competitive.”
AgeX is developing its UniverCyte technology platform at its new 15,700-square-feet R&D facility, in the San Francisco Bay Area, which has current good manufacturing practices (cGMP)-capable manufacturing capacity.
“Universal cells would help us and others to fulfill the original vision of cell therapy,” said Dr. Bailey. “Thus, I am pleased that my colleagues at AgeX and Juvenescence have put together this paper, as it should be of considerable benefit to researchers, possibly enabling them to accelerate their progress.” He added, “AgeX’s UniverCyte technology uses a novel, modified form of the tolerogenic molecule HLA-G, which in nature plays a key role in preventing a mother from rejecting her semi-allogeneic baby.”
The paper is being published online ahead of print on Wednesday, October 30, 2019. It may be found here.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem® and UniverCyte™ manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a whole host of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform named induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem® is AgeX’s delivery technology to stably engraft PureStem cell therapies and slowly release iTR molecules in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications.
For more information, please visit www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.
About Juvenescence
Juvenescence is a life sciences company developing therapies to increase healthy human longevity. It was founded by Jim Mellon, Dr. Greg Bailey and Dr. Declan Doogan. The Juvenescence team are highly experienced drug developers, entrepreneurs and investors with a significant history of success in the life sciences sector. Juvenescence will create, partner with or invest in new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures to develop therapeutics for longevity. Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of aging and seeks to develop therapeutics with the possibility of slowing, halting or potentially reversing elements of aging.
Forward-Looking Statements
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in AgeX’s reports filed with the Securities and Exchange Commissions (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191030005329/en/
Source: AgeX Therapeutics, Inc.
AgeX Therapeutics, Inc.
Dr Nafees Malik, COO
nmalik@agexinc.com
Bill Douglass (Media)
Gotham Communications, LLC
bill@gothamcomm.com
(646) 504-0890
Juvenescence
David Ellam, CFO
david@juvenescence.ltd
AgeX Therapeutics, Inc. 2018
GLTA
HCIT
Yet another new Low of $2.05, all the way from the $5.00+++ When will this stop already, anyone?
GLTA
HCIT
Cincy, yes it is very quiet here and I agree on your post that there is a milestone in 6 months. Hope they are on time for that. I haven't sold but did add a few weeks ago to AGE - GLTU
HCIT
Very quiet here. Everyone sell and leave??
I was actually surprised at the details on the September 9 presentation at Rodman.
Unlike their earlier presentations, this presentation looks more like a legitimate business presentation. They even include a section regarding ANTICIPATED SIX MONTHS MILESTONES. Now let's us see how accountable to fulfilling those MILESTONES. Let's hope there are more ACCOMPLISHED checks than DELAYED OR DROPPED messages after 6 months.
I'm particularly interested in the RENELON category after all the hoopla a couple of years ago.
If we look at last quarterly reports of LCTX, AGE, OCX, do we find any real commercial activity. I see managerial musical chairs, lots of questionable scientific experiments, location moving and disruption, ringing of bells at stock exchanges, and no meaningful timelines leading to revenues.
I once had a hope that Juvenescene would bring some business focus and expertise that would change the culture that has led this BTX empire from a scientists playground into almost oblivion.
Question! Why do any of you still own any of these stocks. I'm preparing to jump ship after waiting, waiting, waiting???
What hopes or catalysts over the next 12 months are convincing to you that make you maintain your positions in any of these enterprises...given the pathetic nature of these quarterly reports?
I don't think they would cringe bobby2. IMO< it's called rejuvination at it's best with a dash of evolutionary regeneration. Just my opinion - gltu
HCIT
I *think* their general plan is to:
(a) Grow early age replacement cells in the lab
(b) Use exosomes to deliver a signal for cells to temporarily express Telomerase (rejuvenates ends of DNA strands for endless copies)
(3) Insert those cells into the body where needed, along with the Small Molecule Cocktail iTR157 (turns on genes for temporary tissue regeneration vs scarring)
I guess this is their version of coming with all guns blazing. Take cells still capable of regeneration, program them to keep their Telomeres completely intact and drug them to continue to regenerate tissues even further.
And I'm also guessing they would cringe to hear the way I just explained things.
Thanks bobby2loaves. Don't quite understand the presentation too much but will have to see their progress in ITR - GLTU
HCIT
LEAF presentation now on Agex's website: https://www.agexinc.com/investors-media/agex-presentations-videos/
Something in AGE's pipeline headed for the clinic?
AgeX Therapeutics’ CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Research
Business Wire - 8:00 AM ET 07/09/19
ALAMEDA, Calif.--(BUSINESS WIRE)-- AgeX Therapeutics, Inc. (AGE) , a biotechnology company focused on therapeutics for human aging, announced today that founder and CEO Michael D. West, Ph.D. will present at Ending Age-Related Diseases: Investment Prospects & Advances in Research, from the Life Extension Advocacy Foundation (LEAF), July 11-12 at The Cooper Union in New York City.
AgeX will participate in the following sessions on Thursday, July 12:
Presentation: As part of the session, “Creating interventions against aging, Part 1” beginning at 9:40am EDT, Dr. West will deliver a 20-minute presentation titled, “The Reversal of the Aging of Human Cells: Strategies for Clinical Implementation.”
Panel: Dr. West will participate on a panel, “Unlocking the Future Without Age-Related Diseases: Forecasts” at 3:50pm.
After rising to $4.00/share recently AGE has topped out obviously and now I am wondering whether the company was waiting for news from Oncocyte's Determavu news which today was not very good at all and I now see AGE shares falling way off by 13% to a LOD so far of $3.36. Just saying but it appears to follow the news from OCX just this morning - GLTA
HCIT
Both are very good reasons for keeping the share price down but it's already increased from 2.55 to where we are now and that was almost a 30% jump for us so somebody knows something or I could just very well could be wrong but I'm holding my shares for a good while since I think they will be successful probably 2020 so GLTU and thank you for replying 2loaves
HCIT
Ahab, the secrecy may be less ludicrous than you think. I can come up with a couple reasons why AGE might want to keep a lid on anything good currently happening:
1. Competition - I know for a fact Michael West does not like to reveal too much about what he's working on, because it gives competitors a glimpse into potential solutions.
2. Share Price Management - Sure, you and I would like for the stock to appreciate Monday morning, as that's cash in the bank for us. But consider the position of guys like Mike West, Greg Bailey and John Mauldin. They directors only have around 100k-200k of shares/options each in this brand spanking new company. If it turns out the company is worth more than today's share price, it would be in their interest to keep that under wraps for as long as possible, so they can pick up some 10-year options on the cheap here. And JUV is obviously in this for the long haul as well, so no great benefit to a near-term share price rise here for them, especially before their IPO due sometime this year, where presumably many would benefit from getting inexpensive shares before it hits the market. Plus, AGE seems loathe to issue any shares whatsoever at this point, so no reason to get the share price up for that. And in fact, I could even see AGE getting private funding from JUV or another private investor, either of whom would probably like the share price low as well.
Bobby2, it's surely a shame things are so quiet here and for all of them to purposely keep secret about what's going on or what's not going on, to me, it's ludicrous to do that especially since they own most of the shares and I would think they'd like to have their investment increase, don't you?
Let's see where shares of AGE top out and whether shares consolidate or retreat 1/2 of the 50% rise this last week or so - GLTU
HCIT
AGE is a black box. I don't think hardly anyone knows what's really going on there, except for its inner circle. That said, if you add up the shares of Juvenescence, Broadwood Capital, Biotime, company insiders and recent option executors, it accounts for about 80% of shares held. So its inner circle is about as large as you will find. As for the 50% share price drop in May, and the 50% share price increase in June, I would say traders used the disappointment of the reduced programs mentioned in the 1Q19 quarterly report to send the stock down, and then traded it back up knowing all the 1Q19 quarterly report really did was tell us AGE is going to be even more mysterious than it already was. AGE looks like either a zero or hero to me. Either management's silence is because nothing is going on, or because there is a lot going on that they don't want to share with others. Personally, I don't think Mike West, Jim Mellon and Greg Bailey all threw in their lot (and $50mm) with AgeX to have it fall apart in the first year. Also notice they haven't had a single share offering since going public in late 2018, and they haven't hyped a single thing about the company: no big press releases, no videos, no conference call.....just a nearly information-less quarterly report. What would you rather see? Mike West, Aubrey de Grey and Russell Skibsted making the rounds, pitching the company and raising money through share offerings? Or a company keeping its head down and efforts secret?
Does anybody know why AGE is up to $3.81 from $2.55 back on May 29th this year? This is a huge move but I don't see any SEC filings nor any news and 1/4ly report isn't due out til August I believe - GLTA
HCIT
Gm and happy Memorial Day to all who lost military members of family and friends. Navy and Army vet here. Was just wondering if there were anything I should worry about here such as notes, fundraisers, etc. TiA
Ps
Already read about having 12 months of operation until they will need additional funding.
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
156
|
Created
|
06/16/11
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |